Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Larry G. who wrote (669)	2/16/2000 10:23:00 PM
From: Pete	Respond to of 792

Larry: The Market I believe would not be huge, but potentially it matbe huge. Limited to hospitials only. These infections are not that common YET. What I do know is that resistant is increasing exponentally. Kinda like compounding growth of cash at 10% , looks small in the beginning but explodes at the end.(Bacteria are fasinating and very adaptable creatures)this growth is like the world's population and hopefully MBI stock(ha!) Pete

To: Larry G. who wrote (669)	2/17/2000 11:32:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 792

It would be interesting to know the target market for MBI 853NL. I believe MBI 853NL has the potential to replace Vancomycin as the drug to treat S. Aureus (SA). Vancomicin is a restricted drug with annual sales of US$250 million (1998). MBI 853NL wont have the same restrictions as placed on Vancomycin which should result in greater sales. The death rate associated with a staph infection is incredibly high. >>Out of these 260,000 infections, 60,000 to 80,000 people die each year. That comes down to 200 people each day (or 8 people every hour). By the time you have finished reading this web page, one person will have died of a Staph infection.<< student.biology.arizona.edu The market for hospital-acquired MRSA is thought to be $20 million annually. >>Vancomycin alone generates about $250 million in sales worldwide. MRSA, which accounts for 108,000 of 270,000 cases of hospital-acquired Staphylococcus aureus (SA) infections in the U.S., could produce sales of more than $20 million, according to estimates by Tarrytown, N.Y.-based AMBI Inc., a biotechnology firm developing two promising strategies against drug-resistant infections.<< the-scientist.library.upenn.edu Any thoughts?